Diagnosis and Treatment of Metabolic Disturbances Associated with HIV and HIV Therapy

Sponsorship Statement

This continuing medical education activity is sponsored by:

Support Statement

This activity is supported by an educational grant from:

Target Audience

The intended audience for this series is cardiologists, endocrinologists, lipidologists, infectious disease specialists, and other healthcare professionals involved in the diagnosis and treatment of patients with HIV-associated lipodystrophy.

Learning Objectives

At the conclusion of this series, participants should be able to:

• Review the evidence about the pathogenesis of HIV-associated lipodystrophy, including pathogenic influences associated with host, disease, and treatment-related factors.
• Diagnose HIV-associated lipodystrophy promptly to improve the overall quality of life in patients with HIV.
• Use a multidisciplinary approach to assess the effects of HIV disease and HAART therapeutic regimens on the metabolic components of lipodystrophy and monitor for metabolic complications on a regular basis.
• Evaluate treatments for HIV-associated lipodystrophy based on their safety, efficacy, dosage requirements, and improvement in patients’ overall quality of life.
• Review the etiology, pathophysiology, and impact on cardiovascular risk of the complex dyslipidemias associated with HIV lipodystrophy.
• Review the evidence concerning the efficacy, safety, drug interactions, and appropriate treatment of the dyslipidemias associated with HIV lipodystrophy to reduce cardiovascular risk.

Overview

Clinicians who manage patients with HIV must be aware of how to screen for, diagnose, and treat metabolic abnormalities and body shape changes. These video interviews will review the pathophysiology of lipoatrophy and lipohypertrophy, common body shape abnormalities observed in patients with HIV. Methods utilized to detect these body shape changes along with challenges associated with their use will also be discussed. Finally, management strategies for these metabolic and body shape abnormalities will be evaluated.

Course Chair

Julian Falutz, MD, FRCPC Director, HIV Metabolic Clinic Senior Physician, Division of Geriatrics McGill University Hospital Center Montreal, Quebec

Faculty

Todd T. Brown, MD, PhD Division of Endocrinology, Diabetes, and Metabolism Johns Hopkins University Baltimore, MD

James A. Underberg, MS, MD, FACPM, FACP, FASH, FNLA Clinical Assistant Professor of Medicine Division of General Internal Medicine NYU Medical School New York, NY

Christine A. Wanke, MD Professor of Medicine and Public Health and Community Medicine Director, Division of Nutrition and Infection Associate Chair, Department of Public Health and Community Medicine Tufts University School of Medicine Boston, MA

Reviewer

W. David Hardy, MD

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™, 0.25 credits per video. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This enduring material is approved for 1 year from the date of original release: October 28, 2013 to October 27, 2014.

How To Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, watch the presentations, complete the CME post-test, and fill in the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as correctly answering 4 out of 5 post-test questions for each video interview. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):

Todd T. Brown, MD, PhD Consulting Fees: Abbott Laboratories, Bristol-Myers Squibb, EMD Serono, Gilead Sciences, Merck & Co., Inc., ViiV Healthcare

Julian Falutz, MD, FRCPC Consulting Fees: Theratechnologies, Inc. Speakers Bureau: Bristol-Myers Squibb, ViiV Healthcare

James A. Underberg, MS, MD, FACPM, FACP, FASH, FNLA Consulting Fees: Aegerion, Genzyme, Health Diagnostics Labs, Liposcience, Novartis, Roche, Sanofi Fees for Non-CME Services: Abbott Laboratories, Amarin, AstraZeneca, Daiichi Sankyo, Inc., Forest Laboratories, Inc., GlaxonSmithKline, Kowa, Merck & Co., Inc., Sanofi

Christine A. Wanke, MD Consulting Fees: Par Pharmaceuticals Other: Adjudicate events for clinical trials, Pfizer

Reviewer reports the following relationship(s):

W. David Hardy, MD Salary: Calimmune, Inc. Consulting Fees: Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck & Co., Inc., Janssen, ViiV Healthcare Contracted Research: Bionor Pharma, Gilead, GlaxoSmithKline – ViiV Healthcare, Janssen, Pfizer – ViiV Healthcare, Vertex Ownership Interest: Merck & Co., Inc.

Vindico Medical Education staff report the following relationship(s):

No relevant financial relationships to disclose.

BetterCME staff report the following relationship(s):

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance. Unlabeled and Investigational Usage: The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices. Copyright Statement: Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2013. Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.